Introducing Fireside Chats: Conversations On Burning Research Topics
Advarra is excited to introduce Fireside Chats, a series of virtual conversations discussing current issues in clinical trials. Each Fireside Chat brings together perspectives from across the research community, enabling…
Q&A Part 1 – Gene Therapy Research in the Age of COVID-19
In Advarra’s inaugural virtual symposium, experts from industry and academia met to discuss the unique challenges gene therapy research poses for research sites, sponsors, CROs, and study participants.
Q&A Part 2 – Gene Therapy Research in the Age of COVID-19
In Advarra’s inaugural virtual symposium, industry and academic experts discussed overcoming obstacles and optimizing study startup in gene therapy research. They respond to more popular Q&A topics here.
Virtual Symposium: Gene Therapy Research in the Age of COVID-19
Gene therapy research is expanding rapidly in the clinical setting, especially in oncology, rare diseases, and infectious diseases—in fact, gene therapy research plays a crucial role in responding to the…
Safety Precautions for Laboratory Research With COVID-19 Specimens
The current global pandemic has brought biosafety to the spotlight. Biosafety practices must be customized to the proposed research as well as the existing facility and local regulatory requirements.
Virtual Symposium: Gene Therapy Research in the Age of COVID-19
Gene therapy research continues its rapid expansion in the clinical setting, especially in infectious disease, rare disease, and oncology. To support discussion of emerging genetic research issues, Advarra presents its…
Safety Precautions for Laboratory Research with SARS-CoV-2 Positive Specimens and COVID-19 Subjects
Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP, Director of Biosafety Services, contributed to the article Safety Precautions for Laboratory Research with SARS-CoV-2 Positive Specimens and COVID-19 Subjects in Clinical Researcher.
How Sites Can Prepare for COVID-19 Genetically Engineered Vaccine Studies
Currently the most prominent coronavirus vaccine candidates contain engineered genetic material. Sites wishing to participate in this research should be prepared for the additional requirements of research involving genetic engineering.
IBC Review and Consulting Services
No more waiting for a standing meeting. No submission deadlines. Responsive and flexible—only 10 business days or less from submission to institutional biosafety committee (IBC) review.